Patents by Inventor Sandip Gavade

Sandip Gavade has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20240018132
    Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula (I) to (IV) for the treatment of cancer.
    Type: Application
    Filed: October 26, 2021
    Publication date: January 18, 2024
    Inventors: Sandip GAVADE, Sangeeta SRIVASTAVA, Prashant KHARKAR, Maithili ATHAVALE
  • Anticancer compounds
    Patent number: 11680078
    Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: June 20, 2023
    Assignee: GODAVARI BIOREFINERIES LTD.
    Inventors: Vitthal Yadav, Maithili Athavale, Prashant Kharkar, Sangeeta Srivastava, Samir Somaiya, Smera Satish, Sandip Gavade
  • USE OF COMPOUNDS FOR TREATING VIRAL INFECTIONS
    Publication number: 20230172958
    Abstract: The invention relates to use of a compound of Formula I for inhibition of V-ATPase activity in a cell and a method of treating viral infections using the compounds of Formula I.
    Type: Application
    Filed: May 10, 2021
    Publication date: June 8, 2023
    Inventors: Maithili ATHAVALE, Sandip GAVADE, Prashant KHARKAR, Sangeeta SRIVASTAVA
  • ANTICANCER COMPOUNDS
    Publication number: 20220389046
    Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.
    Type: Application
    Filed: June 30, 2021
    Publication date: December 8, 2022
    Inventors: Vitthal Yadav, Maithili Athavale, Prashant Kharkar, Sangeeta Srivastava, Samir Somaiya, Smera Satish, Sandip Gavade
  • COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH
    Publication number: 20220073501
    Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula I to XXII for the treatment of cancer.
    Type: Application
    Filed: December 16, 2019
    Publication date: March 10, 2022
    Inventors: Sandip Gavade, Maithili Athavale, Sangeeta Srivastava, Prashant Kharkar
  • Anticancer compounds
    Patent number: 11084843
    Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: August 10, 2021
    Assignee: GODAVARI BIOREFINERIES LTD.
    Inventors: Vitthal Yadav, Maithili Athavale, Prashant Kharkar, Sangeeta Srivastava, Samir Somaiya, Smera Satish, Sandip Gavade
  • ANTICANCER COMPOUNDS
    Publication number: 20190284222
    Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.
    Type: Application
    Filed: April 19, 2018
    Publication date: September 19, 2019
    Inventors: Vitthal Yadav, Maithili Athavale, Prashant Kharkar, Sangeeta Srivastava, Samir Somaiya, Smera Satish, Sandip Gavade
  • EP2 receptor agonists
    Patent number: 9309187
    Abstract: The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: April 12, 2016
    Assignee: Takeda GmbH
    Inventors: Angelika Hoffmeyer, Rainer Boer, Manuela Hessmann, Andreas Pahl, Torsten Dunkern, Simone Hartung, Christof Zitt, Jurgen Volz, Christiane Praechter, Mahindra Makhija, Hiteshkumar Jain, Sandip Gavade, Arati Prabhu, Manojkumar Tiwari, Ashish Keche, Sarvesh Patel
  • Novel EP2 Receptor Agonists
    Publication number: 20150080400
    Abstract: The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.
    Type: Application
    Filed: April 30, 2013
    Publication date: March 19, 2015
    Applicant: TAKEDA GMBH
    Inventors: Angelika Hoffmeyer, Rainer Boer, Manuela Hessmann, Andreas Pahl, Torsten Dunkern, Simone Hartung, Christof Zitt, Jurgen Volz, Christiane Praechter, Mahindra Makhija, Hiteshkumar Jain, Sandip Gavade, Arati Prabhu, Manojkumar Tiwari, Ashish Keche, Sarvesh Patel